Chinese Journal of Emergency and Critical Care Nursing >
Nursing care of cardiotoxic adverse reactions caused by immune checkpoint inhibitors in patients with lung cancer
To summarize the nursing experience of three lung cancer patients with cardiotoxic reactions after treatment with immune checkpoint inhibitors. Key points of care included timely assessment and monitoring of cardiotoxicity，safe drug administration to reduce cardiotoxic reactions，application of multidisciplinary nursing cooperation model to improve specialized nursing，implementing personalized discharge follow-up to promote early recovery of patients. After timely intervention，close monitoring and comprehensive management，one patient recovered well and continued immunotherapy，and two patients were treated with palliative therapy after stopping immunotherapy. The condition of three patients in this group was stable during six-month follow-up.
HU Han , FENG Dan , HE Junfeng . Nursing care of cardiotoxic adverse reactions caused by immune checkpoint inhibitors in patients with lung cancer[J]. Chinese Journal of Emergency and Critical Care Nursing, 2025 , 6(1) : 86 -88 . DOI: 10.3761/j.issn.2096-7446.2025.01.014
| [1] | 周彩存, 王洁, 步宏, 等. 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版)[J]. 中国肺癌杂志, 2020, 23(2):65-76. |
| Zhou CC, Wang J, Bu H, et al. Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer(2019 version)[J]. Chin J Lung Cancer, 2020, 23(2):65-76. | |
| [2] | 中华医学会呼吸病学分会肺癌学组. 免疫检查点抑制剂相关肺炎诊治专家共识[J]. 中华结核和呼吸杂志, 2019, 42(11):820-825. |
| Lung Cancer Group of Respiratory Branch of Chinese Medical Association. Expert consensus on the diagnosis and treatment of pneumonia related to immune checkpoint inhibitors[J]. Chin J Tubere Respir Dis, 2019, 42(11):820-825. | |
| [3] | 孙涛. 2023版CSCO肿瘤心脏病学指南中化疗及免疫治疗心脏毒性的更新要点解读[J]. 实用肿瘤杂志, 2023, 38(5):434-439. |
| Sun T. Interpretation of updates of 2023 CSCO guidelines for oncology cardiology:chemotherapy and immunotherapy section[J]. J Pract Oncol, 2023, 38(5):434-439. | |
| [4] | Kennedy LC, Wong KM, Kamat NV, et al. Untangling the multidisciplinary care web:streamlining care through an immune-related adverse events(IRAE) tumor board[J]. Target Oncol, 2020, 15(4):541-548. |
| [5] | Swami U, Monga V, Bossler AD, et al. Durable clinical benefit in patients with advanced cutaneous melanoma after discontinuation of anti-PD-1 therapies due to immune-related adverse events[J]. J Oncol, 2019,2019:1856594. |
| [6] | Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib[J]. J Am Coll Cardiol, 2019, 74(13):1667-1678. |
| [7] | 段磊, 胡宝祥, 司继刚. 糖皮质激素冲击治疗引发的不良反应及对策[J]. 儿科药学杂志, 2018, 24(1):51-53. |
| Duan L, Hu BX, Si JG. Adverse reactions and strategies of glucocorticoid impulse therapy[J]. J Pediatr Pharm, 2018, 24(1):51-53. | |
| [8] | 江淑芬, 董畅, 刘莹, 等. 免疫检查点抑制剂相关心血管不良反应的机制、临床表现及管理[J]. 中华心血管病杂志, 2021, 49(4):410-413. |
| Jiang SF, Dong C, Liu Y, et al. Mechanism,clinical manifestations and management of cardiovascular adverse reactions associated with immune checkpoint inhibitors[J]. Chin J Cardiol, 2021, 49(4):410-413. | |
| [9] | Ederhy S, Voisin AL, Champiat S. Myocarditis with immune check-point blockade[J]. N Engl J Med, 2017, 376(3):290-291. |
/
| 〈 |
|
〉 |